Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) that is approved by the Food and Drug Administration (FDA) for the treatment of obsessive-compulsive disorder and depression. Fluvoxamine is not FDA-approved for the treatment of any infection.

Fluvoxamine was discovered to bind to sigma-1 receptors which results in reduced production of inflammatory cytokines and inflammatory genes.

There is insufficient evidence for the COVID-19 Treatment Guidelines Panel to recommend either for or against the use of fluvoxamine for the treatment of COVID-19

SOURCE: https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/fluvoxamine/